The effect of repeated oral doses of azelastine hydrochloride on antipyrine half-life in normal volunteers.
Treatment with azelastine 4.4 mg twice daily for 21 days did not produce any change in salivary antipyrine elimination in 8 normal volunteers.
D000328:Adult; D000983:Antipyrine / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010793:Phthalazines / Q000009:adverse effects / Q000494:pharmacology*; D011724:Pyridazines / Q000494:pharmacology*; D012463:Saliva / Q000378:metabolism
D006634:Histamine H1 Antagonists; D010793:Phthalazines; D011724:Pyridazines; D000983:Antipyrine; C020976:azelastine